American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung CancerChristopher G. Azzoli, Giuseppe Giaccone, Sherman Baker et al.|Journal of Clinical Oncology|2009Cited by 913
Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M MutationGeoffrey R. Oxnard, Vincent A. Miller, Maria E. Arcila et al.|Clinical Cancer Research|2010Cited by 624
Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based AssayMaria E. Arcila, Marc Ladanyi, Geoffrey R. Oxnard et al.|Clinical Cancer Research|2011Cited by 574
Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer ModelingJuliann Chmielecki, William Pao, Agnès Viale et al.|Science Translational Medicine|2011Cited by 530
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor <i>BRAF</i> gene mutations but lack mutations in <i>KRAS, NRAS,</i> or <i>MEK1</i>Kadoaki Ohashi, William Pao|Proceedings of the National Academy of Sciences|2012Cited by 436